Document Detail


Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis.
MedLine Citation:
PMID:  17420199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: A meta-analysis of randomized, controlled trials that evaluated the effect of the macrolide antibiotic, azithromycin, on clinical outcomes in patients with coronary artery disease (CAD) was conducted. METHODS: A systematic literature search of MEDLINE, EMBASE, Web of Science, and the Cochrane Database of Systematic Reviews was conducted using specific search terms. Randomized, controlled trials comparing azithromycin or placebo in secondary CAD patients with adequately reported data on mortality and clinical cardiac endpoints were included. A random-effects model was used. RESULTS: Six studies (n=13,778) met the inclusion criteria. The trials varied in their design. On meta-analysis, azithromycin resulted in a nonsignificant reduction in mortality versus placebo (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.77-1.09; p=0.31). Four trials reported the rate of nonfatal myocardial infarction (MI). Azithromycin did not have an effect on the rate of nonfatal MI versus placebo (OR, 0.95; 95% CI, 0.80-1.13; p=0.57). Five trials reported rates of hospitalization in which no significant difference was seen with azithromycin versus placebo (OR, 0.97; 95% CI, 0.80-1.17; p=0.76). Six trials were used to evaluate the composite cardiovascular endpoint. Again, no significant benefit was seen with azithromycin versus placebo (OR, 0.93; 95% CI, 0.84-1.03; p=0.218). CONCLUSION: Meta-analysis showed that azithromycin does not appear to reduce the frequency of recurrent cardiac events in patients with CAD. Results from ongoing trials may clarify the role of azithromycin in the secondary prevention of coronary events.
Authors:
William L Baker; Kimberly A Couch
Related Documents :
19041049 - Prognostic importance of change in qrs duration over time associated with left ventricu...
16086939 - Inhospital and 1-year mortality of patients who develop worsening renal function follow...
12654609 - Why are patients with chronic obstructive pulmonary disease at increased risk of cardio...
12228779 - Management of ventricular arrhythmias in diverse populations in california.
12390949 - Comparative survival of dialysis patients in the united states after coronary angioplas...
19371959 - Transatlantic similarities and differences in major natural history endpoints of heart ...
7623059 - Spurious st segment depression by automated st segment analysis.
2949679 - Use of tissue plasminogen activator in the emergency department for acute myocardial in...
8768779 - Cardioversion of atrial fibrillation. state of the art, 1995.
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  64     ISSN:  1079-2082     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-10     Completed Date:  2007-06-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  830-6     Citation Subset:  IM    
Affiliation:
School of Pharmacy, University of Connecticut, Storrs, and Division of Cardiology, Hartford Hospital 06102, USA. wbaker01@harthosp.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use*
Azithromycin / therapeutic use*
Chlamydophila Infections / drug therapy*
Chlamydophila pneumoniae / drug effects
Coronary Artery Disease / prevention & control*
Hospitalization
Humans
Models, Statistical
Myocardial Infarction / drug therapy
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 83905-01-5/Azithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Next Document:  Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded ster...